New vaccine could stop people developing the highly infectious illness after early trial results found it creates a βstrong immune responseβ
Britain could become the first country to offer norovirus jab after early trial results found it creates a βstrong immune responseβ.
Wes Streeting, the Health Secretary, said achieving the world-first could reduce the βhuge strainβ the NHS faces every winter and save taxpayers millions.
Scientists hope the new vaccine from Moderna could stop people developing the vomiting and diarrhoea bug, which often spreads in care homes and isΒ linked to around 12,000 hospital admissionsΒ in Britain every year.
The jab will enter final stages of testing within the next two weeks.
Intradermal Mycobacterium vaccae and obuense (IMM-101) Oral Non-typeable Haemophilus influenzae (NTHi) UK could be first country to offer norovirus jab against βwinter vomiting bugβ New vaccine could stop people developing the highly infectious illness after early trial results found it creates a βstrong immune responseβ
mRNA Based
Trial evaluates the efficacy and safety of mRNA-1403 Aims to recruit 2,500 participants, UK, late October to early 2025 Some mobile sites for community visits 25,000 globally Half mRNA, half placebo 18 years + but 60 + wanted <
Single dose vaccine at the first visit – a jab given in the upper arm.
The Nova 301 trial serves as a model for future collaborations between the public and private sectors in advancing medical research.
Should the norovirus jab prove successful, (Read well,Should) the company expects to submit a marketing application to regulators in 2026, with the review process expected to take up to a year. Further trials would also be carried out in teenagers and younger children.
